EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

Edvan Q Crusoé iD, Glaciano Ribeiro, João Tadeu D Souto Filho iD, Jayr Schmidt Filho, Natalia Schutz, Milton A F Aranha iD, Abel Costa iD, Abrahao Hallack iD, Fernando V Pericole, Juliana S Lima iD, Breno Gusmão, Eduardo Flávio O Ribeiro und 9 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2321-2325

DOI: 10.1111/bjh.70775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 27.08.2026. Verfasst von Edvan Q Crusoé und 20 weiteren Autor:innen. Beteiligte Einrichtung: Rede D'Or Oncologia, Salvador, Brazil. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

lenalidomide maintenancemultiple myelomareal‐world outcomes

Autor:innen und Institutionen

  • Rede D'Or Oncologia, Salvador, Brazil.
  • Universidade Federal da Bahia, Salvador, Brazil.
  • Clinica Hematológica, Belo Horizonte, Brazil.
  • Faculdade de Medicina de Campos, Campos dos Goytacazes, Brazil.
  • A.C. Camargo Cancer Center-Rua Prof. Antônio Prudente, São Paulo, Brazil.
  • Hospital Italiano, Ciudad Autónoma de Buenos Aires, Argentina.

ORCID-Profile: Edvan Q Crusoé, João Tadeu D Souto Filho, Milton A F Aranha, Abel Costa, Abrahao Hallack, Juliana S Lima, Jorge P Vaz, Rosane Bittencourt, Ederson R Mattos, Vania Hungria

Zitieren

APA

Crusoé, E. Q., Ribeiro, G., Souto Filho, J. T. D., Schmidt Filho, J., Schutz, N., Aranha, M. A. F., Costa, A., Hallack, A., Pericole, F. V., Lima, J. S., Gusmão, B., Ribeiro, E. F. O., Vaz, J. P., Bittencourt, R., Cunha, R., Ovigli, D., Berg, L., Mattos, E. R., Maiolino, A., …, & GBRAM (2026). Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. British Journal of Haematology, 209(5), 2321-2325. https://doi.org/10.1111/bjh.70775

Vancouver

Crusoé EQ, Ribeiro G, Souto Filho JTD, Schmidt Filho J, Schutz N, Aranha MAF, et al. Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma. British Journal of Haematology. 2026;209(5):2321-2325. doi:10.1111/bjh.70775

BibTeX
@article{Cruso2026,
  author = {Crusoé, Edvan Q and Ribeiro, Glaciano and Souto Filho, João Tadeu D and Schmidt Filho, Jayr and Schutz, Natalia and Aranha, Milton A F and Costa, Abel and Hallack, Abrahao and Pericole, Fernando V and Lima, Juliana S and Gusmão, Breno and Ribeiro, Eduardo Flávio O and Vaz, Jorge P and Bittencourt, Rosane and Cunha, Rafael and Ovigli, Danielle and Berg, Luiza and Mattos, Ederson R and Maiolino, Angelo and Hungria, Vania and GBRAM, GBRAM},
  title = {Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2321--2325},
  doi = {10.1111/bjh.70775}
}
Kostenlos starten →